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production of NGF from keratinocytes.
NGF, through its high-affinity receptor
TrkA, seems to have a central role
in pruritus (Indo, 2010). Moreover,
histamine causes increased NGF levels
in human keratinocytes (Kanda and
Watanabe, 2003), and scratching
behavior significantly correlates with
high NGF levels (Yamaoka et al.,
2007). Thus, it may be speculated that
NGF, released in high levels from
keratinocytes in AD patients and
further enhanced by CGRP in an auto-
crine manner, as well as neuropeptide-
induced histamine and trypase release
from mast cells, contribute to pruritus in
AD. On one hand, it can be argued that,
lacking the immunological component,
this model cannot mimic all aspects of
AD. On the other hand, pure immuno-
logical models thus far fail to integrate
the recognized interplay between the
epidermis and the nervous system. In
addition, given the reduced expression
of filaggrin, it is tempting to speculate
that the first trigger in the pathogenesis
of AD could take place in the
dysregulated barrier, thus inducing an
upregulation of NGF in keratinocytes,
followed by the above described
cascade of events eventually leading to
keratinocyte proliferation and epidermal
thickening, accompanied by further
production of NGF giving rise to a
vicious circle. This scenario would
initially take place without primary
intervention of the adaptive immune
system that would subsequently amplify
epidermal and nerve response. Vice
versa, we are in substantial need of
better in vivo models that explain the
complex pathophysiology of how the
adaptive immune system, represented
mainly by the TH2-helper cell and IgE-
producing B cells in AD, or even
dendritic cells, regulate neuro-immune
responses in AD, neurogenic inflamma-
tion, and pruritus, which are definitely a
part of the pathophysiology of AD. Taken
together, in vivo models that integrate the
pathophysiological changes of the
resident skin cells, the adaptive and
innate immune system, and the skin
nervous system are in great demand for
understanding the ‘‘outside-in’’ versus the
‘‘inside-out’’ hypotheses in AD.
In sum, the AD model presented by
Roggenkamp et al. is an important step,
one that can be improved even more to
reproduce the disease pathophysiology
of AD in vivo. In particular, it will be of
great interest to evaluate the model after
blocking the activity of NGF in the
presence or absence of the immuno-
logical component. Finally, the model
described by Roggenkamp et al. could
be exploited to evaluate the efficacy of
the treatment of AD and its related
pruritus, with molecules other than anti-
histamines and immunosuppressants.
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Photosensitivity in the Elderly—Think
of Late-Onset Protoporphyria
Jorge Frank1,2, Pamela Poblete-Gutie´rrez3,4 and Norbert J. Neumann1,2
Photosensitivity is the clinical hallmark of both erythropoietic protoporphyria
(EPP) and X-linked dominant protoporphyria (XLDPP). Both disorders result from
a hereditary dysfunction in heme biosynthesis. Disease onset is usually in early
childhood. However, rare patients with late-onset EPP in association with a
myeloproliferative disorder or myelodysplastic syndrome have been reported. In
this issue, Livideanu et al. describe the first patient with late-onset XLDPP.
Journal of Investigative Dermatology (2013) 133, 1467–1471. doi:10.1038/jid.2013.80
Photosensitivity as the clinical hallmark of
photodermatoses
Photosensitivity comprises any increase
in cutaneous reactivity to sunlight.
Sunlight is composed of B50% visible,
40% infrared, and 10% UV radiation
(Millard and Hawk, 2002). The
biological effects of visible light (electro-
magnetic spectrum 400–800 nm) on the
skin are mostly negligible. However, in
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exceptional cases, patients with marked
photosensitization as in chronic actinic
dermatitis or solar urticaria may be
sensitive to visible light. In higher doses,
infrared light (electromagnetic spectrum
800–105 nm) can cause thermal damage
and contributes significantly to the
process of photoaging. Furthermore,
erythema ab igne is due to infrared
irradiation. In contrast to the aforemen-
tioned sunlight spectra, UV light (elec-
tromagnetic spectrum 40–400 nm) is the
major factor contributing to photosensi-
tivity and can cause and aggravate a
broad variety of skin diseases, which are
collectively known as photodermatoses
or photoaggravated dermatoses.
UV radiation is composed of three
different spectra. UVC light (electromag-
netic spectrum 40–290 nm) comprises
the shortest wave lengths. It is filtered
by the ozone layer in the strato-
sphere and, therefore, does not
usually reach the surface of the earth.
UVB light (electromagnetic spectrum
280–320 nm) reaches maximum inten-
sity when it is directly overhead and
filtering is therefore minimal. This radia-
tion is responsible for solar erythema
(sunburn). UVA light is subdivided
into UVA2 (electromagnetic spectrum
320–340 nm) and UVA1 (electro-
magnetic spectrum 340–400 nm) radia-
tion. It reaches the earth’s surface too,
but it has less toxic effects than
the shorter UV wavelengths. The inten-
sity of UVA is 500–1,000-fold higher
compared with UVB. Thus, under
natural conditions, UVA irradiation
causes both erythema and skin darken-
ing. In contrast to UVB, UVA light is
able to penetrate window glass and,
therefore, photosensitivity reactions
may also occur indoors or inside
a car (Lehmann, 2009; Trakatelli
et al., 2009).
Upon exposure to UV radiation, every
individual will exhibit different degrees
of a physiological skin reaction that
includes acute and subacute effects such
as erythema, pigmentation, darkening,
delayed tanning, epidermal hyperplasia,
immunologic changes, and vitamin D3
synthesis. In contrast, chronic effects
mainly comprise photoaging and
photocarcinogenesis.
In particularly susceptible individuals,
however, exposure of the skin to UV or,
in rare instances, visible light results in
an abnormal photosensitivity reaction
and, subsequently, the manifestation of
a photodermatosis or photoaggravated
dermatosis (Morison, 2004; Lehmann,
2009).
Regarding the differential diagnosis of
photodermatoses and choice of the ade-
quate diagnostic procedures, two points
are of major importance:
(1) Are we dealing with an acute or
chronic photosensitivity reaction?
(2) At what age did the symptoms first
occur?
Acute versus chronic photosensitivity
Acute cutaneous reactions are often
episodic and usually follow a specific
exposure to sunlight or an indoor source
of light such as a tanning device. Each
episode has a defined course that can
last minutes, hours, days, and even X1
week. Of note, the patient does not have
symptoms between episodes. In con-
trast, chronic photosensitivity may man-
ifest as a reaction that lasts through the
spring or summer months only or that
persists year-round. Importantly, the
severity of the reaction mostly bears
little relation to the particular exposure
to sunlight. Table 1 gives an overview
on frequent and rare photodermatoses
Clinical Implications
 Erythropoietic protoporphyria is a hereditary metabolic photosensitivity
disorder characterized by episodes of moderate-to-severe acute cuta-
neous photosensitivity that usually commences in infancy and may
include burning, itching, stinging, pain, erythema, and edema on the
sun-exposed skin areas.
 Besides acquired or inherited diseases like solar dermatitis, solar urticaria,
polymorphous light eruption, lipoid proteinosis, hydroa vacciniforme, and
lupus erythematosus, the most important differential diagnosis of ery-
thropoietic protoporphyria is X-linked dominant protoporphyria, which is
clinically undistinguishable.
 Although the disease onset of both erythropoietic protoporphyria and
X-linked dominant protoporphyria is commonly in infancy and childhood,
first onset at old age has been reported and, therefore, has to be
considered as a rare differential diagnosis for photosensitivity in the
elderly, particularly in association with a medical history of myeloproli-
ferative disorder or myelodysplastic syndrome.
Table 1. Photodermatoses characterized by acute and chronic
photosensitivity
Acute photosensitivity Chronic photosensitivity
Disease Incidence Disease Frequency
Polymorphous light eruption Very
common
Chronic actinic dermatitis Rare
Subacute cutaneous lupus
erythematosus
Common Actinic prurigo Rare
Drug-induced phototoxicity Uncommon Photoexacerbated atopic
eczema
Rare
Protoporphyria Rare Porphyria cutanea tarda Rare
Solar urticaria Rare Systemic lupus erythematosus Rare
Photoallergy
(usually caused by sunscreens)
Rare Dermatomyositis Rare
Modified from Morison, 2004.
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manifesting with either acute or chronic
photosensitivity (Morison, 2004).
Age of onset of photosensitivity
In a patient with a cutaneous disorder
induced by sunlight, an important hint
toward the correct diagnosis is to deter-
mine at what age the skin symptoms
first occurred. When the photoderma-
tosis occurs in childhood, the most
important differential diagnosis will
usually be juvenile spring eruption and
polymorphous light eruption, followed
by protoporphyria and actinic prurigo.
In contrast, in an elderly patient, the
leading differential diagnosis will
mostly be between chronic actinic der-
matitis and drug-induced photosensitiv-
ity; but photoaggravated dermatoses
also have to be excluded. Table 2 lists
the most common photodermatoses
with consideration of their age of onset
(Trakatelli et al., 2009).
Classification of photodermatoses
Independent of the acuteness and the
different stages of life at which photo-
sensitivity occurs, photodermatoses
can be classified into four groups: (1)
immunologically mediated photoderma-
toses; (2) chemical- and drug-induced
photosensitivity diseases; (3) photoag-
gravated dermatoses; and (4) hereditary
photosensitivity disorders. The latter
group is also referred to as genophoto-
dermatoses and can be further subdi-
vided into defects of nucleotide excision
repair, DNA helicase, cholesterol synth-
esis, and heme biosynthesis (Trakatelli
et al., 2009; Santoro and Lim, 2011).
Defects of heme biosynthesis and the
porphyrias
Heme is synthesized by eight consecu-
tive enzymatic steps of which the first
and the last three take place in the
mitochondrion, whereas the other four
conversions are catalyzed in the
cytosol. Dysfunction of any of these
enzymes results in a specific type of
predominantly inherited rare metabolic
disorders, which are collectively known
as porphyrias (Figure 1).
Clinically, most of the porphyrias
manifest skin symptoms, which are con-
fined to the sun-exposed areas of the
body. Thus, from a dermatologist’s view
these diseases can be classified into
cutaneous and noncutaneous forms.
Only in two types of porphyrias, skin
symptoms do not occur, acute intermit-
tent porphyria and d-aminolevulinic
acid dehydratase deficiency porphyria,
which are both characterized by the
occurrence of potentially life-threaten-
ing acute neurovisceral attacks (Table 3)
Table 2. Most common photodermatoses according to their age of onset
Childhood Adulthood Old age
Juvenile spring eruption Polymorphous light eruption Chronic actinic dermatitis
Polymorphous light eruption Drug-induced photosensitivity Drug-induced photosensitivity
Protoporphyria Solar urticaria Cutaneous T-cell lymphoma
Actinic prurigo Lupus erythematosus Dermatomyositis
Hydroa vacciniforme Porphyria cutanea tarda
Modified from Roelandts, 2000.
ALA synthase 2
ALA dehydratase
PBG deaminase
Uroporphyrinogen III
cosynthase
Uroporphyrinogen
decarboxylase
Coproporphyrinogen
oxidase
Protoporphyrinogen
oxidase
Ferrochelatase
ALA-dedydratase
deficiency porphyria
Acute intermittent
porphyria
Congenital erythropoietic
porphyria
Porphyria cutanea
tarda
Hereditary
coproporphyria
Variegate
porphyria
Erythropoietic
protoporphyria
Glycine + Succinyl CoA
Δ-AMINOLEVULINIC acid (ALA)
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Hydroxymethylbilane
Uroporphyrinogen III
Coproporphyrinogen III
Protoporphyrinogen IX
Protoporphyrin IX
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MITOCHONDRION
CYTOSOL
X-linked dominant
protoporphyria
Figure 1. The pathway of porphyrin–heme biosynthesis. X-linked dominant protoporphyria results from a dysfunction in the isoform 2 of ALA synthase.
Erythropoietic protoporphyria is due to a defect in ferrochelatase.
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(Puy et al., 2010; van Serooskerken
et al., 2010).
Within the group of cutaneous
porphyrias, skin symptoms can vary
considerably with regard to acuity and
age of onset. Furthermore, they show a
broad degree of intra- and interfamilial
variation regarding specific efflores-
cences and subjective symptoms like
itching, burning, stinging, and pain. As
a general rule, however, two groups of
cutaneous porphyrias can be differen-
tiated based on (1) the occurrence or
absence of vesiculae and bullae and
(2) the age of onset. With regard to the
former, patients with porphyria cutanea
tarda, variegate porphyria, here-
ditary coproporphyria, and congenital
erythropoeitic porphyria usually show
blistering, whereas erythropoietic proto-
porphyria (EPP) and X-linked dominant
protoporphyria (XLDPP) do not. Clini-
cally, EPP and XLDPP are characterized
by painful, burning, stinging, and itching
cutaneous sensations, which can
develop within seconds to minutes of
sun exposure, usually followed by
erythema and edema of the skin. Pete-
chiae and purpura may also be seen but
are uncommon, as is the occurrence of
vesiculae. Chronic UV light exposure
can lead to lichenification, postinflam-
matory hyperpigmentation, and scar-
ring, particularly over the knuckles and
on the nose. The disease usually com-
mences early in infancy or childhood
with episodes of worsening during
spring and summer (Lecluse et al.,
2008; Frank and Poblete-Gutierrez,
2011). Thus, the characteristic cutane-
ous symptoms and their acuity in
combination with the early age of
onset make EPP and XLDPP unique
among the cutaneous porphyrias.
EPP (Online Mendelian Inheritance in
Man (OMIM) 177000) is the second
most common type of cutaneous por-
phyria and results from a partial defi-
ciency of ferrochelatase (FECH), the
last enzyme in heme biosynthesis
(Figure 1). Without racial or sex predi-
lection, the disease has an estimated
prevalence of 1 in 130,000 and is
inherited in an autosomal semidomi-
nant manner (Puy et al., 2010; van
Serooskerken et al., 2010).
The differential diagnosis includes
other acquired or inherited diseases
such as solar dermatitis, solar urticaria,
polymorphous light eruption, lipoid pro-
teinosis, hydroa vacciniforme, and lupus
erythematosus. The most important dif-
ferential diagnosis, however, is XLDPP
(OMIM 300752) (Figure 1). This very
rare type of porphyria has only recently
been recognized as an own entity and is
clinically undistinguishable from EPP
(Table 3) (Whatley et al., 2008).
In both EPP and XLDPP, a significant
increase in erythrocyte protoporphyrin
of more than five to ten times the
normal level of B1.2mmol l1 can be
detected. In the case of EPP, the major
part is free protoporphyrin, whereas in
XLDPP high amounts of zinc protopor-
phyrin rather than free protoporphyrin
can be encountered.
On the genetic level, EPP is caused by
inactivating mutations in the FECH gene
on chromosome 18q21.3. In contrast, acti-
vating mutations in the isoform 2 of the
d-aminolevulinic acid synthase (ALAS2)
gene on chromosome Xp11.21 give rise
to the phenotype observed in XLDPP
(Whatley et al., 2008; Puy et al., 2010).
Although the symptoms in EPP
usually occur in early infancy, very rare
Table 3. Classification of the porphyrias into cutaneous and noncutaneous forms
Porphyria type Incidence Age of onset Clinic
Cutaneous porphyrias
Porphyria cutanea tarda Most common porphyria
worldwide
Third to fourth decade of life Moderate-to-severe photosensitivity. Vesicles, bullae,
skin fragility, erosions, crusts, milia, scarring,
hyperpigmentation and hypertrichosis. Indistinguishable
from variegate porphyria and hereditary coproporphyria.
Erythropoietic
protoporphyria
Second highest incidence
of the cutaneous porphyrias
Early childhood (1–4 years); late
onset extremely rare
Painful erythema, edema, purpura, skin thickening, waxy
scars. In B5% of patients severe liver disease.
X-linked dominant
protoporphyria
Extremely rare Early childhood (1–4 years) Skin symptoms indistinguishable from erythropoietic
protoporphyria. Liver disease.
Variegate porphyria B1 per 300 in South Africa;
relatively rare elsewhere
Second to third decade of life;
usually not before puberty
Skin symptoms similar to porphyria cutanea tarda. Acute
neurovisceral attacks similar to acute intermittent
porphyria (neurocutaneous porphyria).
Hereditary coproporphyria Very rare Usually not before puberty Skin symptoms similar to porphyria cutanea tarda. Acute
neurovisceral attacks similar to acute intermittent
porphyria (neurocutaneous porphyria).
Congenital erythropoietic
porphyria
Very rare Infancy/first decade of life Vesicles, bullae, erosions, ulcerations, crusts, milia,
scarring, hyperpigmentation and hypertrichosis.
Mutilation; hemolytic anemia; hepatosplenomegaly;
erythrodontia. Very severe clinical course.
Noncutaneous porphyrias
Acute intermittent porphyria 0.5–1 per 100,000 Second to fourth decade of life;
rarely before puberty
Acute neurovisceral attacks. No photosensitivity.
d-Aminolevulinic acid
dehydratase deficiency
porphyria
Extremely rare Early and late onset possible Acute neurovisceral attacks similar to acute intermittent
porphyria. No photosensitivity.
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cases of late-onset EPP have been
reported. In these patients, the uncom-
mon age of onset often hampers
establishing the correct diagnosis. To
date, all individuals diagnosed with
late-onset EPP had a medical history of
either associated myeloproliferative
disorder or myelodysplastic syndrome
(Goodwin et al., 2006). The latter issue
may delay diagnosis even more, mainly
for two reasons First, the photosensitivity
sometimes gets less attention than the
associated, potentially life-threatening
hematological disease. Second, these
patients are primarily seen by
hematologists and oncologists who are
sometimes overwhelmed with the
assessment of cutaneous symptoms.
With this in mind, we would like to
express our compliments for the work
delivered by Livideanu et al. (2013) who
shed new light on late-onset protopor-
phyria in this issue of the Journal of
Investigative Dermatology by the identi-
fication and molecular genetic charac-
terization of the first XLDPP patient with
disease onset at old age. Based on the
medical history of an 89-year-old male
and the clinical findings, the authors
develop the diagnostic path to establish-
ing the diagnosis in the elderly with
a photodermatosis. After excluding
drug-associated photosensitivity, they
unequivocally confirm the presence of
a somatic hematopoietic mosaicism by
biochemical porphyrin analysis, deter-
mination of ferrochelatase activity,
cytogenetic studies and, eventually,
sequencing of the ALAS2 gene in both
blood and hair bulb cells of the affected
individual. The results are presented in a
stringent and well-structured manner
and put into context with previous data
on late-onset EPP. Without doubt, this
report provides both an excellent clin-
ical and scientific approach to an old
patient with acute onset of photosensi-
tivity, thereby demonstrating that even
in the elderly you have to think of rare
exceptions to the rule that protopor-
phyria usually becomes manifest in
infancy.
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